{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:32:04Z","timestamp":1787671924494,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00535-026-02429-x","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:44:14Z","timestamp":1777715054000},"page":"1207-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective IL-23 inhibitors in ulcerative colitis: current evidence and perspectives for multimodal personalized treatment: a narrative review"],"prefix":"10.1007","volume":"61","author":[{"given":"Ichitaro","family":"Horiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-1025","authenticated-orcid":false,"given":"Akira","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"2429_CR1","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41591-021-01520-5","volume":"27","author":"M Friedrich","year":"2021","unstructured":"Friedrich M, Pohin M, Jackson MA, et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med. 2021;27:1970\u201381.","journal-title":"Nat Med"},{"key":"2429_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12876-022-02559-5","volume":"22","author":"R Goll","year":"2022","unstructured":"Goll R, Moe \u00d8K, Johnsen KM, et al. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease. BMC Gastroenterol. 2022;22:464.","journal-title":"BMC Gastroenterol"},{"key":"2429_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/apt.14422","volume":"47","author":"S Singh","year":"2018","unstructured":"Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"2429_CR4","first-page":"656","volume":"15","author":"S Fine","year":"2019","unstructured":"Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to anti\u2013tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2019;15:656\u201365.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2429_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","journal-title":"J Exp Med"},{"key":"2429_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2429_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00054725-200501000-00003","volume":"11","author":"C Schmidt","year":"2005","unstructured":"Schmidt C, Giese T, Ludwig B, et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn\u2019s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11:16\u201323.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 2","key":"2429_CR8","doi-asserted-by":"publisher","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","volume":"16","author":"R Atreya","year":"2022","unstructured":"Atreya R, Neurath MF. IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality. J Crohns Colitis. 2022;16(Suppl 2):ii54-63.","journal-title":"J Crohns Colitis"},{"key":"2429_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","volume":"168","author":"AR Bourgonje","year":"2025","unstructured":"Bourgonje AR, Ungaro RC, Mehandru S, et al. Targeting the interleukin 23 pathway in inflammatory bowel disease. Gastroenterology. 2025;168:29-52.e3.","journal-title":"Gastroenterology"},{"key":"2429_CR10","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"2429_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae200","volume":"19","author":"J van Oostrom","year":"2025","unstructured":"van Oostrom J, Hanzel J, Verstockt B, et al. Anti-TNF non-response in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profiles. J Crohns Colitis. 2025;19:jjae200.","journal-title":"J Crohns Colitis"},{"key":"2429_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385:628\u201339.","journal-title":"N Engl J Med"},{"key":"2429_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97236-0","volume":"11","author":"KJ Roberts","year":"2021","unstructured":"Roberts KJ, Cubitt MF, Carlton TM, et al. Preclinical development of a bispecific TNF\u03b1\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep. 2021;11:19422.","journal-title":"Sci Rep"},{"key":"2429_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2468-1253(25)00296-1","volume":"11","author":"V Jairath","year":"2026","unstructured":"Jairath V, Danese S, D\u2019Haens GR, et al. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomized, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol. 2026;11:34\u201345.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2429_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2429_CR16","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/ibd.22936","volume":"18","author":"S Serada","year":"2012","unstructured":"Serada S, Fujimoto M, Terabe F, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18:2169\u201379.","journal-title":"Inflamm Bowel Dis"},{"key":"2429_CR17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"2429_CR18","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"2429_CR19","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.3390\/jcm14155180","volume":"14","author":"S Ukai","year":"2025","unstructured":"Ukai S, Horiuchi I, Terashima T, et al. Assessment of ulcerative colitis patients with elevated neutrophilic infiltration in the colonic mucosal epithelium using the Komagane subclassification of the Geboes score Grade 3. J Clin Med. 2025;14:5180.","journal-title":"J Clin Med"},{"key":"2429_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","volume":"56","author":"S Shinzaki","year":"2021","unstructured":"Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol. 2021;56:560\u20139.","journal-title":"J Gastroenterol"},{"key":"2429_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/ibd\/izac230","volume":"29","author":"T Shimoyama","year":"2023","unstructured":"Shimoyama T, Yamamoto T, Yoshiyama S, et al. Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for evaluating clinical and endoscopic disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2023;29:1399\u2013408.","journal-title":"Inflamm Bowel Dis"},{"key":"2429_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5217\/ir.2023.00135","volume":"22","author":"R Karashima","year":"2024","unstructured":"Karashima R, Sagami S, Yamana Y, et al. Early change in serum leucine-rich alpha-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis. Intest Res. 2024;22:473\u201383.","journal-title":"Intest Res"},{"key":"2429_CR23","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.3390\/jcm13102957","volume":"17","author":"I Horiuchi","year":"2024","unstructured":"Horiuchi I, Horiuchi K, Horiuchi A, et al. Serum leucine-rich alpha-2 glycoprotein could be a useful biomarker to differentiate patients with normal colonic mucosa from those with inflammatory bowel disease or other forms of colitis. J Clin Med. 2024;17:2957.","journal-title":"J Clin Med"},{"key":"2429_CR24","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.3390\/jcm14082803","volume":"14","author":"B Aksoy","year":"2025","unstructured":"Aksoy B, \u00c7a\u011fan Appak Y, Ak\u015fit M, et al. Leucine-rich alpha-2 glycoprotein 1 as a biomarker for evaluation of inflammatory bowel disease activity in children. J Clin Med. 2025;14:2803.","journal-title":"J Clin Med"},{"key":"2429_CR25","first-page":"176","volume":"58","author":"AG R\u00f8seth","year":"1997","unstructured":"R\u00f8seth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176\u201380.","journal-title":"Digestion"},{"key":"2429_CR26","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","volume":"70","author":"A Jukic","year":"2021","unstructured":"Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021;70:1978\u201388.","journal-title":"Gut"},{"key":"2429_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/ibd\/izac095","volume":"29","author":"K Kawashima","year":"2023","unstructured":"Kawashima K, Oshima N, Kishimoto K, et al. Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm Bowel Dis. 2023;29:359\u201366.","journal-title":"Inflamm Bowel Dis"},{"key":"2429_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"2429_CR29","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385:1280\u201391.","journal-title":"N Engl J Med"},{"key":"2429_CR30","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159\u201371.","journal-title":"Lancet"},{"key":"2429_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","volume":"159","author":"H Yoon","year":"2020","unstructured":"Yoon H, Jangi S, Dulai PS, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology. 2020;159:1262\u201375.","journal-title":"Gastroenterology"},{"key":"2429_CR32","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1053\/j.gastro.2020.12.024","volume":"160","author":"M Iacucci","year":"2021","unstructured":"Iacucci M, Smith SCL, Bazarova A, et al. An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in ulcerative colitis. Gastroenterology. 2021;160:1558\u201369.","journal-title":"Gastroenterology"},{"key":"2429_CR33","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV Jr, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307\u201343.","journal-title":"Gastroenterology"},{"key":"2429_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1490667","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Sun H, Wang Q, et al. Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1490667.","journal-title":"Front Pharmacol"},{"key":"2429_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.","journal-title":"Nat Rev Dis Primers"},{"key":"2429_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated diseases. Nat Med. 2015;21:719\u201329.","journal-title":"Nat Med"},{"key":"2429_CR37","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.4049\/jimmunol.1101494","volume":"188","author":"A Zwiers","year":"2012","unstructured":"Zwiers A, Kraal L, van de Pouw Kraan TC, et al. Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J Immunol. 2012;188:1573\u20137.","journal-title":"J Immunol"},{"key":"2429_CR38","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"2429_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/mi.2011.54","volume":"5","author":"JH Cox","year":"2012","unstructured":"Cox JH, Kljavin NM, Ota N, et al. Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis. Mucosal Immunol. 2012;5:99\u2013109.","journal-title":"Mucosal Immunol"},{"key":"2429_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nri.2017.10","volume":"17","author":"O Soehnlein","year":"2017","unstructured":"Soehnlein O, Steffens S, Hidalgo A, et al. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. 2017;17:248\u201361.","journal-title":"Nat Rev Immunol"},{"key":"2429_CR41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1172\/JCI76693","volume":"125","author":"G Leoni","year":"2015","unstructured":"Leoni G, Neumann PA, Kamaly N, et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest. 2015;125:1215\u201327.","journal-title":"J Clin Invest"},{"key":"2429_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.47.3.404","volume":"47","author":"K Geboes","year":"2000","unstructured":"Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404\u20139.","journal-title":"Gut"},{"key":"2429_CR43","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.3390\/jcm14207214","volume":"14","author":"I Horiuchi","year":"2025","unstructured":"Horiuchi I, Horiuchi A, Horiuchi K, et al. Geboes histopathology score Grade 3 subclassification predicts treatment response in active ulcerative colitis. J Clin Med. 2025;14:7214.","journal-title":"J Clin Med"},{"key":"2429_CR44","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R, et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024;332:881\u201397.","journal-title":"JAMA"},{"key":"2429_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","volume":"405","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Allegretti JR, Pan\u00e9s J, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405:33\u201349.","journal-title":"Lancet"},{"key":"2429_CR46","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izae253","volume":"31","author":"BE Sands","year":"2025","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, et al. Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2025;31:1876\u201390.","journal-title":"Inflamm Bowel Dis"},{"key":"2429_CR47","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"2429_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257\u201365.","journal-title":"Gastroenterology"},{"key":"2429_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85\u201395.","journal-title":"Gastroenterology"},{"key":"2429_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96\u2013109.","journal-title":"Gastroenterology"},{"key":"2429_CR51","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomized trials. Lancet. 2022;399:2113\u201328.","journal-title":"Lancet"},{"key":"2429_CR52","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"2429_CR53","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384.","journal-title":"Lancet"},{"key":"2429_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf144","volume":"19","author":"CL Pugliano","year":"2025","unstructured":"Pugliano CL, Liang RF, Ruffa A, et al. Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters? J Crohns Colitis. 2025;19:jjaf144.","journal-title":"J Crohns Colitis"},{"key":"2429_CR55","first-page":"1026","volume":"30","author":"PM Irving","year":"2024","unstructured":"Irving PM, Hur P, Gautam R, et al. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: evidence from a systematic literature review. J Manag Care Spec Pharm. 2024;30:1026\u201340.","journal-title":"J Manag Care Spec Pharm"},{"key":"2429_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186476","volume":"14","author":"EM Mastoridou","year":"2025","unstructured":"Mastoridou EM, Fousekis FS, Sakellariou XM, et al. The cardiovascular effects of inflammatory bowel disease therapy with biologics and small molecules: a comprehensive review. J Clin Med. 2025;14:6476.","journal-title":"J Clin Med"},{"key":"2429_CR57","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK, et al. An oral interleukin-23-receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390:510\u201321.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02429-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:07:44Z","timestamp":1787670464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02429-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02429-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}